Stocks and Investing Stocks and Investing
Tue, November 2, 2021
Mon, November 1, 2021

Leland Gershell Upgraded (ALNY) to Buy and Held Target at $200 on, Nov 1st, 2021


Published on 2024-10-27 18:26:57 - WOPRAI, Leland Gershell
  Print publication without navigation


Leland Gershell of Oppenheimer, Upgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Buy and Held Target at $200 on, Nov 1st, 2021.

Leland has made no other calls on ALNY in the last 4 months.



There are 9 other peers that have a rating on ALNY. Out of the 9 peers that are also analyzing ALNY, 3 agree with Leland's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $108 on, Thursday, October 28th, 2021
  • Gary Nachman of "BMO Capital" Maintained at Hold with Increased Target to $196 on, Friday, August 27th, 2021
  • Edward Tenthoff of "Piper Sandler" Downgraded from Buy to Hold and Held Target at $181 on, Wednesday, August 4th, 2021


These are the ratings of the 6 analyists that currently disagree with Leland


  • David Lebowitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $226 on, Friday, October 29th, 2021
  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $200 on, Friday, October 29th, 2021
  • Esther Rajavelu of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $215 on, Monday, October 4th, 2021
  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $250 on, Friday, August 13th, 2021
  • David Lebovitz of "Morgan Stanley" Maintained at Buy with Increased Target to $234 on, Wednesday, August 4th, 2021
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $216 on, Wednesday, August 4th, 2021
Contributing Sources